Oxford University Hospitals NHS
NHS Foundation Trust

Paediatric Research Team
LG1-10-15, Children's Hospital
Headley Way, Oxford
OX3 9DU
01865 231729/ bleep 4403
childrensresearch@paediatrics.ox.ac.uk

Burden of RSV Disease

Study Information Booklet

You are invited to take part in a study to determine the burden of disease due to Respiratory Syncytial Virus (RSV), the commonest virus causing coughs,colds and chest infections in young children. The study is being run by Oxford University Hospitals NHS Foundation Trsut and the Oxford Vaccine Group (OVG) which is part of the University of Oxford.

Before you decide whether to take part, it is important for you to understand what the study is about and what participation would involve. Please take time to read the information carefully, and discuss with others if you wish. If anything is unclear or you would like further information please contact the study team (details below).

Thank you for taking the time to consider taking part in the study.

Who are the Oxford Vaccine Group?

The Oxford Vaccine Group is part of the University of Oxford and is an independent research team of doctors, nurses and play assistants. We carry out research studies on infectious diseases and vaccines for babies, young children, teenagers and adults and teach doctors and nurses about immunisations. In the past 5 years alone, over 7000 participants in the Thames Valley area have taken part in our research studies.

Why have I been approached about the study?

You have been approached about the study because either;

- You are pregnant and are attending appointments in an area that is taking part in this research study

Or

- You have recently given birth to a healthy infant born at 37 weeks of gestational age or later

This study intends to recruit 2000 new-borns across the Thames Valley and South Midlands' area.

What is Respiratory Syncytial Virus (RSV) and why is important?

RSV is the commonest virus causing coughs, colds and chest infections in infants. More than half of children will be infected in the first year of life, mostly during the winter. Most infections are mild (runny nose, cough and cold), but in some cases infants develop a severe chest infection requiring admission to hospital. In the winter months, RSV is responsible for around 1 in 6 of all hospital admissions in infants in the UK. Worldwide, RSV is the second largest cause of death in children under one year of age after malaria, mostly in Africa and Asia. In addition, about half of children who develop an RSV chest infection go on to have symptoms of asthma, including wheezing and coughing, for the next few years. Currently, there is no curative treatment or vaccine for prevention of RSV.

What is the purpose of the study?

The main purpose of this study is to determine the burden of disease due to Respiratory Syncytial Virus (RSV) in young children. It aims to understand how frequently children are infected with RSV, which children are most severely affected and what symptoms continue in the years after an infection.

Is my child eligible for this study?

Your child can participate in this study if he or she was born at least 37 weeks of gestational age, is less than 8 days old and does not have any severe medical condition.

Does my child need to take part in this study?

Taking part in this study is completely voluntary and if you decide to say no, it will not affect your child's routine care in any way. You are also free to change your mind and withdraw your child at any time without giving an explanation.

What happens in the study?

If you decide you would like to take part in this study, a member of the research team either from the hospital you are attending or from the Oxford Vaccine Group (OVG) would talk you through the study and answer any questions you may have before asking you to sign a consent form.

If your baby hasn't been born when you sign the consent form, we would ask your permission to access your medical records to track when you give birth. A member of the research team will then make contact with you to confirm you still wish to take part. A visit will be scheduled with you either in the hospital, or at home (by a member of the OVG research team).

Birth

Doctors or nurses from the research team will ask questions about your health and the delivery of your baby. Information about the delivery may also, with your permission be taken from you and your child's medical records.

Follow-up

We will contact you again around the time of your child's first birthday to ask you to complete a questionnaire by telephone, email or on-line about your child and your family's health. If your child has been admitted to a hospital we would, with your permission, take information about the admission from your child's medical records. Children that have been admitted to a hospital for a respiratory illness will be followed up every year. The study will run for 3 years and if you decide to take part, we will be able to tell you how many years you and your child would be followed up for, although it would be for a maximum of 3 years.

Active follow-up for a sub set of children

Another aim of the study is to see if we can find out whether a child is more likely to have severe RSV infection or have longer lasting symptoms by looking for certain indicators called biomarkers. These biomarkers can be found in blood, mucous, other body fluids and in the DNA. 200 children will have samples taken and will be followed up more closely than your child.

What are the possible risks and discomforts of taking part of his study?

There are no risks associated with this study.

What are the benefits of taking part of the study?

By taking part of the study your child will not have a direct benefit, nonetheless, other children may benefit in the future from what is learned in this study.

Would my child's taking part in this study be kept confidential?

Any research study records with you or your child's name and address would be held confidentially by the research staff in the hospital you attended. When you have been discharged from the hospital, the research study records (which are different from NHS medical records) will be transferred confidentially to the OVG research team, who will continue the care of your child in this study.

All the information collected for the study will be coded with a study number and kept strictly confidential. Only authorised study staff can access you or your child's data. No data that identifies you or your child will leave the research sites (local hospital or OVG). Following completion of the study, all study records (which includes some personal data such as name, date of birth and contact details) will be retained up to 3 years after the youngest participant reaches 18 years of age. We would also seek your permission to use the data in future related research. Files will be confidentially destroyed if storage is no longer required.

By signing the consent form for this study, you would be giving permission for the research staff in your local hospital and OVG, representatives of the Sponsor (Oxford University) and appropriate regulatory authorities to look at you and your child's medical records and study records.

We will inform your child's GP and health visitor that s/he is taking part in this study.

Who else can see my child's study records?

In order to ensure that the study is being conducted correctly the study records can be inspected by the Clinical Trials and Research Governance Office (CTRG), University

of Oxford, without violating yours child's confidentiality. This group is responsible for ensuring the appropriate conduct of the research on behalf of the research sponsor (the University of Oxford).

The RESCEU Consortium

This study is part of a wider group of studies all trying to understand the burden of RSV infection. In total 10,000 children will be enrolled in countries across Europe. Experts from Universities, hospitals and laboratories have formed a group called RESCEU (Respiratory Syncytial virus Consortium in Europe) to carry out these studies and test samples taken. The anonymised data collected from you and your child will be combined and shared with the group of experts to help understand the burden of RSV infection in Europe. Neither you nor your child will be identifiable from the data shared with the consortium. The anonymous electronic data will be stored on a secure server held by the University of Utrecht (a partner of the RESCEU consortium).

Who is organising and funding the research?

The study is funded by the Innovative Medicines Initiative (IMI), which is a joint undertaking between the European Union (EU) and the pharmaceutical industry association (EFPIA), and is being sponsored by University of Oxford.

What will happen if I don't want my child to carry on with the study?

You can change your mind and withdraw your child from the study at any time without giving any reason. If you change your mind and withdraw your child from the study we would use the data we have collected up until the point you informed us that you wanted to withdraw, unless you inform us in writing that you wish for your child's data to be destroyed.

What will happen at the end of the research study?

You will receive a summary of the study results when the study ends. To allow for full analysis of all participants' data, this information will be released about one to two years after the last child completes their participation in the study.

All OVG publications will appear on the OVG website and you will receive a letter containing these results. Your child would not be identified in any report or publication and we will not provide individual results.

If you are interested in hearing about other research studies that we may be running in the future then there is an option to sign up to a contact list through which we can get in touch. This does not oblige you in any way to take part in the future research.

What if I wish to complain?

If you wish to complain about any aspect of the way you have been approached or treated during the course of this study, you should contact the Oxford Vaccine Group on 01865 611400 or email info@ovg.ox.ac.uk. You can also contact the University of Oxford Clinical Trials and Research Governance (CTRG) office on 01865 572224 or email the Head of CTRG Heather House ctrg@admin.ox.ac.uk. Alternatively, you can contact the Patient Advice and Liaison Service (PALS) in your local hospital on 01865 221473 or email PALS@ouh.nhs.uk.

What if something goes wrong?

The University of Oxford, as Sponsor, has appropriate insurance in place in the unlikely event that your child suffers any harm as a direct consequence of participating in this study.

What else do I need to know?

All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect participant's interests. This study has been reviewed and given favourable opinion by South Central – Oxford B Research Ethics Committee.

In summary:

- This study will help to determine the burden of RSV infection in children.
- 2000 newborns will be followed from birth to their first year of life and you will be asked to complete a yearly questionaire. No bloods or any other samples will be taken from your child.
- If your child is admitted to the hospital for an acute respiratory illness during the first year of life, he/she will be followed up for a maximum of 3 years by yearly questionnaires

What do I do now?

You do not need to make a final decision straight away. Please contact us by:

Calling the Paediatric Research Team at the Children's Hospital:

- Telephone: 01865 231729
- Email: childrensresearch@paediatrics.ox.ac.uk

Or by contacting the Oxford Vaccine Group

- e-mail: info@ovg.ox.ac.uk
- Telephone: 01865 11400
- Website: babyrsv.org

Members of the research team will be happy to discuss the study with you and answer any questions you may have.
Thank you for considering taking part in this study.
Yours sincerely,

Dr Matthew Snape
Chief Investigator
Consultant Vaccinologist and Paediatrician
Honorary Senior Clinical Lecturer

Dr Simon Drysdale
Principal Investigator